Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer
Phase 3
Terminated
- Conditions
- NauseaNeoplasms
- Registration Number
- NCT00124930
- Lead Sponsor
- Alberta Health services
- Brief Summary
The purpose of this study is to compare the efficacy and safety of Haldol (haloperidol) and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.
- Detailed Description
The purpose of this study is to compare the efficacy and safety of haloperidol and olanzapine in the control of chronic nausea with advanced cancer patients who have failed first line antiemetic therapy.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
- >18 years of age
- Significant nausea/vomiting
- Failed maxeran and domperidone
- Underlying treatment of causes has failed
- Adequate cognitive function
- Communicates well
Exclusion Criteria
- Partial/complete bowel obstruction
- Currently taking Haldol or olanzapine
- Has drug induced extrapyramidal symptoms
- Parkinson's disease
- Undergoing chemotherapy or radiotherapy (RT) to brain, abdomen, stomach or esophagus
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Severity of nausea on days 3 and 5
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada